Administrative  and Scientific Advisory Boards
  • Treat Neuromuscular Disease Therapeutics Advisory Committee
  • Foundation advisor:  PKD Foundation, IRSF
  • European Institute of Oncology Drug Discovery Advisor
  • CDRD Commercial Advisory Board .  University of British Columbia
  • Synergenics.  
  • VBPharma (founder)
  • Synergenics Science Partner
  • Psychogenics
  • ADMETRx.  In vitro ADME tools and expertise.
  • Michigan High Throughput Screening Center.  Custom small molecule chemical library and high
    throughput screening
  • UCB.  Oncology, CNS, and Inflammatory Diseases, small molecule and biologics.  UK and Belgium
  • CINRG.  Muscular Dystrophy preclinical and clinical multi-site team
  • PKD Foundation Task Force
  • Reaction Biology.  Novel technologies for high throughput screening
  • Verseon.  Novel modeling and drug design technology, US and India
  • Treat NMD Therapeutics Advisory Committee, Core Member
  • Deciphera.  Non-ATP mimetic kinase inhibitors
  • PharmOptima.  Variety of high skill pharmacology services including adme and whole animal
    pharmacology
  • CeeTox.  Cellular models of predictive toxicity.
  • Lycera.  Novel CNS drugs based on benzodiazepine scaffolds

Selected Active Consulting Activities
  • Bioenergenix.  Kinase company created as a virtual.  Responsible for chemistry.  Co-founder
  • Neuromed.  medicinal chemistry
  • University of Rochester, Michigan State University, University of Wisconsin Milwaukee, Harvard
  • Mlk3 Kinase.  University of Rochester grant
  • Receptors LLC.  Novel affinity ligand creation
  • Xenon.  Medicinal Chemistry
  • Genentech. Technology evaluation
  • YourEncore.  Facilitated access to retired scientists
  • Venture groups: Atlas, Scientia, Hope Therapeutcis
  • NatureNorth.  Natural products from birch bark
  • Knopp Neuroscience.  GMP and CMC work.
  • Atlas Ventures

NIH / NINDS Activities
  • Chair, NINDS Spinal Muscular Atrophy Development Project.  Created a virtual discovery company
    (medicinal chemistry, in vitro and in vivo biology, adme, safety) on this multi-year, multi-million dollar
    project that is targeting a disease modifying treatment for SMA.  Project is at the candidate
    selection / Pre-IND stage with a stop codon readthrough compound.
  • Co-chair of NINDS Translational Research Evaluation Committee
  • Member, NINDS NSDA Study Section
John M. McCall

Selected and Active Projects
Return to Home